Chief Financial Officer
Mr. Michael Tomsicek has served as our Chief Financial Officer since November 2017. He brings significant experience in corporate finance, operations management systems and corporate collaborations and licensing. Prior to joining our company, Mike served as Chief Financial Officer of Abiomed, a publicly-traded provider of medical devices, from July 2015 to August 2017. Before that, he was Chief Financial Officer at Cubist Pharmaceuticals. He was at Cubist from August 2010 to January 2015, through the company’s sale to Merck, and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing through a period of dynamic growth. Prior to Cubist, Mike spent nearly eight years at General Electric Healthcare, ultimately as Chief Financial Officer of the global ultrasound business. Mike holds an M.B.A. and a B.S. in Engineering, both from the University of Wisconsin.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.